This review of monarchE and TRADE data demonstrates that abemaciclib dose modifications manage treatment-related adverse events without compromising efficacy in high-risk HR+, HER2− early breast cancer.
Michelle Corso
Advertisement
Articles by Michelle Corso
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Analyzing ADC Options Across Metastatic TNBC
2
Arlo-Cel Produces Deep Responses in Pretreated R/R Multiple Myeloma
3
64 A Phase I/II Study of Pembrolizumab and Anti-CD3 x Anti-HER2 Armed Activated T-Cells in Metastatic Breast Cancer
4
Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma
5